MannKind Corporation Q1 FY2026 earnings call

Michael Castagna started by discussing the company's strategy to evolve into a diversified company. Announced Mankind 1501 as Relenopeg DPI with potential $35 million in development milestones and 10% royalty on net sales. Talked about Q1 performance challenges including structural, transitional, and inventory adjustment issues but noted underlying indicators were encouraging. Highlighted Q1 highlights like FDA approval of updated AFREZA label, completion of launch build-out for Afrezza pediatrics, pilot phase enrollment in inhale first pediatric trial, settlement of convertible notes, and progress in SC farm integration. Discussed strategic evolution from single product company to diversified cardiometabolic and orphan lung company. Outlined major catalysts for 2026 and beyond including AFREZA pediatric indication, Furosix ReadyFlow Auto Injector, and Mankind 201 Natetnib DPI program. Chris Prentice reviewed financials, mentioned R&D and SG&A expenses, balance sheet position, and plans for commercial launches and pipeline advancement.

Quarterly revenues were $90 million, a 15% increase over the prior year. Furosix net sales in Q1 2026 were $15.5 million. Afreza Global Sales Q1 2026 net sales were $15.3 million, up 3% year over year. Tyveso DPI-related revenues were $23.5 million for the quarter. Royalties in Q1 2026 were $32.7 million, up 9% year over year.

Remains on track to meet full year 2026 revenue target of $110 to $120 million. Believes sufficient capital to support planned commercial launches and pipeline advancement. Credit facility provides financial flexibility if needed.

Questions and answers include inquiries about Relinopeg DPI product progress, Nintedinib DPI program, Furosix trends, Relentag DPI process, Afreza Pediatrics contracting and ramp, 201 program details, discharge protocols integration, and Furosix PDUFA and transition